钇-90选择性内放射治疗肝脏恶性肿瘤核医学全程管理中国专家共识(2026)

Chinese expert consensus on nuclear medicine full-course management for yttrium-90 selective internal radiation therapy for malignant liver tumors (2026)

  • 摘要: 钇-90选择性内放射治疗(90Y-SIRT)在我国肝脏恶性肿瘤治疗中的应用不断拓展,但不同医疗中心在患者筛选、99Tcm-大颗粒聚合白蛋白(MAA)模拟评估、个体化剂量规划、微球输注、治疗后剂量验证及辐射安全管理等方面仍存在差异。为规范90Y-SIRT核医学全程管理,本共识围绕90Y-SIRT患者准入与多学科协作(MDT)、99Tcm-MAA mapping、肺分流与肿瘤靶向性评估、个体化剂量学、介入治疗实施、治疗后90Y PET/CT或SPECT/CT分布与剂量验证、疗效评估、长期随访、并发症管理及辐射防护等关键环节提出规范化建议,构建以核医学全程管理为主轴的MDT标准化实践框架,旨在促进我国90Y-SIRT安全、规范、同质化开展,并为医疗机构建立标准操作流程、人员培训和质量控制体系提供参考。

     

    Abstract: Yttrium-90 selective internal radiation therapy (90Y-SIRT) has been increasingly applied in the management of hepatic malignancies in China. However, differences remain among medical centers in patient selection, technetium-99m macroaggregated albumin (99Tcm-MAA) simulation and evaluation, individualized dose planning, microsphere administration, post-treatment dose verification, and radiation safety management. To standardize comprehensive nuclear medicine management throughout the 90Y-SIRT treatment, this consensus provides standardized recommendations covering key aspects such as patient eligibility and multidisciplinary team (MDT), 99Tcm-MAA mapping, assessment of lung shunting and tumor targeting, individualized dosimetry, implementation of interventional treatment, post-treatment 90Y PET/CT or SPECT/CT distribution and dose verification, response assessment, long-term follow-up, complication management, and radiation protection. By establishing a standardized practice framework centered on comprehensive nuclear medicine management and incorporating MDT collaboration, this consensus aims to promote safe, standardized, and homogeneous implementation of 90Y-SIRT in China and to provide a reference for medical institutions to establish standard operating procedures, professional training, and quality control systems.

     

/

返回文章
返回